Mivacurium: A novel, short-acting, nondepolarizing muscle relaxant

Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. Therefore, pharmacokinetics influence the onset time of submaximal neuromuscular block. These results imply that to obtain an ultrashort onset time, muscle relaxants should be developed that not only have a low affinity for the receptor but also rapidly disappear from plasma.

show abstract

Inhibition of the Enzymic Degradation of Suxamethonium and Mivacurium Increases the Onset Time of Submaximal Neuromuscular Block

Beaufort¹,

Nigrovic²,

Proost

et al. 1998

Anesthesiology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Mivacurium: A novel, short-acting, nondepolarizing muscle relaxant

Cited by 1 publication

References 68 publications

Inhibition of the Enzymic Degradation of Suxamethonium and Mivacurium Increases the Onset Time of Submaximal Neuromuscular Block

Inhibition of the Enzymic Degradation of Suxamethonium and Mivacurium Increases the Onset Time of Submaximal Neuromuscular Block

Contact Info

Product

Resources

About